How Model-Based Meta-Analysis Leverages Public Data to Support Strategic Drug Development Decision Making

MBMA represents a smart, quantitative approach to enable a sponsor to supplement its existing proprietary drug data with public preclinical and clinical data, allowing it to make more informed strategic drug development decisions. MBMA involves the systematic search and tabulation of summary results from external data sources and their combination with in-house clinical trial data to create a richer resource…

Author(s): Mark Lovern

返回顶部
Powered by Translations.com GlobalLink OneLink Software